Related Experiment Video

Updated: Feb 22, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

CDK4/6 inhibition in early and metastatic breast cancer: A review

A F de Groot1, C J Kuijpers1, J R Kroep1

  • 1Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands.

Cancer Treatment Reviews
|September 30, 2017
PubMed

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors offer effective treatment for metastatic breast cancer (BC) by halting tumor cell growth. This review examines clinical trials of these CDK4/6 inhibitors in advanced and adjuvant settings.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast cancer (BC) remains a significant cause of cancer-related mortality in women.
  • Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a novel therapeutic class for BC treatment.
  • These inhibitors induce G1 cell cycle arrest, potentially impeding tumor progression.

Purpose of the Study:

  • To review completed and ongoing clinical trials of CDK4/6 inhibitors in advanced breast cancer (aBC).
  • To assess the efficacy and tolerability of palbociclib, ribociclib, and abemaciclib in various treatment settings.
  • To discuss future perspectives for CDK4/6 inhibitors in breast cancer management.

Main Methods:

  • Systematic review of principal completed and ongoing clinical trials in aBC.
  • Analysis of data from trials investigating palbociclib, ribociclib, and abemaciclib.
  • Inclusion of information on both metastatic and (neo)adjuvant settings.

Main Results:

  • Palbociclib and ribociclib have received FDA/EMA approval for specific advanced HR+ HER2- BC patient populations.
  • CDK4/6 inhibitors demonstrate promising outcomes in the (neo)adjuvant treatment of breast cancer.
  • Ongoing trials continue to evaluate the role of these agents across different BC stages.

Conclusions:

  • CDK4/6 inhibitors are a valuable addition to breast cancer therapy, particularly for advanced disease.
  • Further research and ongoing trials are crucial for optimizing the use of CDK4/6 inhibitors.
  • These agents hold significant promise for improving outcomes in both metastatic and early-stage breast cancer.
Keywords:
AbemaciclibBreast cancerCDK4/6 inhibitionCyclin-dependent kinase 4/6PalbociclibRibociclib

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K